Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular disease

Li, Xiaoying; Li, Li; Na, Sang-Hoon; Santilli, Francesca; Shi, Zhicai; Blaha, Michael J.

doi:10.1016/j.ajpc.2022.100363

Cited by 2 publications

(2 citation statements)

References 128 publications

(148 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequent works and expert opinions reworked this type of evidence, thereby suggesting that in patients at higher cardiovascular risk (e.g., T2DM patients) the benefit of antiplatelet therapy exceeds the bleeding risk [174]. Nowadays, several international guidelines report different types of indications for the use of antiplatelet therapy in primary prevention, thus creating heterogeneity in prescription methods [175].…”

Section: Implications For Antiplatelet Therapy In Primary Preventionmentioning

confidence: 99%

Platelet, Antiplatelet Therapy and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review

Boccatonda,

Del Cane,

Marola

et al. 2024

Life

Self Cite

View full text Add to dashboard Cite

Metabolic-associated fatty liver disease (MASLD) is not only related to traditional cardiovascular risk factors like T2DM and obesity, but it is also an independent risk factor for the development of cardiovascular disease. MASLD has been shown to be independently related to endothelial dysfunction and atherosclerosis. MASLD is characterized by a chronic proinflammatory response that, in turn, may induce a prothrombotic state. Several mechanisms such as endothelial and platelet dysfunction, changes in the coagulative factors, and lower fibrinolytic activity can contribute to induce the prothrombotic state. Platelets are players and aggressors of metabolic dysregulation; obesity and insulin resistance are related to platelet hyperactivation. Furthermore, platelets can exert a direct effect on liver cells, particularly through the release of mediators from granules. Growing data in the literature support the use of antiplatelet agent as a treatment for MASLD. The use of antiplatelets drugs seems to exert beneficial effects on HCC prevention in patients with MASLD, since platelets contribute to fibrosis progression and cancer development. This review aims to summarize the main data on the role of platelets in the pathogenesis of MAFLD and its main complications such as cardiovascular events and the development of liver fibrosis. Furthermore, we examine the role of antiplatelet therapy not only in the prevention and treatment of cardiovascular events but also as a possible anti-fibrotic and anti-tumor agent.

show abstract

Section: Implications For Antiplatelet Therapy In Primary Preventionmentioning

confidence: 99%

Platelet, Antiplatelet Therapy and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review

Boccatonda,

Del Cane,

Marola

et al. 2024

Life

Self Cite

View full text Add to dashboard Cite

show abstract

“…T2DM patients) the benefit of antiplatelet therapy exceeds the bleeding risk [152]. Nowadays, several international guidelines report different types of indications for the use of antiplatelet therapy in primary prevention, thus creating heterogeneity in prescription methods [153].…”

Section: Implications For Antiplatelet Therapy In Primary Preventionmentioning

confidence: 99%

Platelet, Antiplatelet Therapy and Masld: A Narrative Review

Boccatonda,

Del Cane,

Marola

et al. 2024

Preprint

View full text Add to dashboard Cite

Metabolic-associated fatty liver disease (MASLD) is not only associated with traditional cardiovascular risk factors such as T2DM and obesity, but it is also an independent risk factor for the development of cardiovascular disease. MASLD has been shown to be independently related to endothelial dysfunction and atherosclerosis. MASLD is characterized by a chronic proinflammatory response that, in turn, may induce a prothrombotic state. Several mechanisms such as endothelial and platelet dysfunction, changes in the coagulation cascade, decreased fibrinolytic activity can contribute to induce the prothrombotic state. Platelets are players and addresses of metabolic dysregulation; obesity and insulin resistance are related to platelet hyperactivation. Furthermore, platelets can exert a direct effect on liver cells, particularly through the release of mediators from granules. Growing data in literature support the use of antiplatelet agent as a treatment for MASLD. The use of antiplatelets drugs seems to have potential clinical implication for the prevention of HCC patients with MASLD, since platelets contribute to fibrosis progression and cancer development. This review aims to summarize the main data on the role of platelets in the pathogenesis of MAFLD and its main complications such as cardiovascular events and the development of liver fibrosis. Furthermore, we will examine the role of antiplatelet therapy not only in the prevention and treatment of cardiovascular events but also as a possible anti-fibrotic and anti-tumor agent.

show abstract

Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular disease

Cited by 2 publications

References 128 publications

Platelet, Antiplatelet Therapy and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review

Platelet, Antiplatelet Therapy and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review

Platelet, Antiplatelet Therapy and Masld: A Narrative Review

Contact Info

Product

Resources

About